BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, Imai Y, Shima T, Kanbara Y, Saibara T, Mori T, Kawata S, Uto H, Takami S, Sumida Y, Takamura T, Kawanaka M, Okanoue T; Japan NASH Study Group, Ministry of Health, Labour, and Welfare of Japan. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011;9:428-433; quiz e50. [PMID: 21320639 DOI: 10.1016/j.cgh.2011.01.023] [Cited by in Crossref: 258] [Cited by in F6Publishing: 226] [Article Influence: 25.8] [Reference Citation Analysis]
Number Citing Articles
1 Rahman R, Hammoud GM, Almashhrawi AA, Ahmed KT, Ibdah JA. Primary hepatocellular carcinoma and metabolic syndrome: An update. World J Gastrointest Oncol. 2013;5:186-194. [PMID: 24069511 DOI: 10.4251/wjgo.v5.i9.186] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 44] [Article Influence: 6.4] [Reference Citation Analysis]
2 Zhang Y, Wang C, Xu H, Xiao P, Gao Y. Hepatocellular carcinoma in the noncirrhotic liver: a literature review. Eur J Gastroenterol Hepatol 2019;31:743-8. [PMID: 31008808 DOI: 10.1097/MEG.0000000000001419] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Kang SH, Lee HW, Yoo JJ, Cho Y, Kim SU, Lee TH, Jang BK, Kim SG, Ahn SB, Kim H, Jun DW, Choi JI, Song DS, Kim W, Jeong SW, Kim MY, Koh H, Jeong S, Lee JW, Cho YK; Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:363-401. [PMID: 34154309 DOI: 10.3350/cmh.2021.0178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism. 2016;65:1017-1025. [PMID: 26997539 DOI: 10.1016/j.metabol.2016.01.012] [Cited by in Crossref: 186] [Cited by in F6Publishing: 159] [Article Influence: 37.2] [Reference Citation Analysis]
5 Eduful BJ, O'Byrne SN, Temme L, Asquith CRM, Liang Y, Picado A, Pilotte JR, Hossain MA, Wells CI, Zuercher WJ, Catta-Preta CMC, Zonzini Ramos P, Santiago AS, Couñago RM, Langendorf CG, Nay K, Oakhill JS, Pulliam TL, Lin C, Awad D, Willson TM, Frigo DE, Scott JW, Drewry DH. Hinge Binder Scaffold Hopping Identifies Potent Calcium/Calmodulin-Dependent Protein Kinase Kinase 2 (CAMKK2) Inhibitor Chemotypes. J Med Chem 2021;64:10849-77. [PMID: 34264658 DOI: 10.1021/acs.jmedchem.0c02274] [Reference Citation Analysis]
6 Abe M, Miyake T, Kuno A, Imai Y, Sawai Y, Hino K, Hara Y, Hige S, Sakamoto M, Yamada G, Kage M, Korenaga M, Hiasa Y, Mizokami M, Narimatsu H. Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol 2015;50:776-84. [DOI: 10.1007/s00535-014-1007-2] [Cited by in Crossref: 104] [Cited by in F6Publishing: 95] [Article Influence: 14.9] [Reference Citation Analysis]
7 Fenoglio L, Serraino C, Castagna E, Cardellicchio A, Pomero F, Grosso M, Senore C. Epidemiology, clinical-treatment patterns and outcome in 256 hepatocellular carcinoma cases. World J Gastroenterol 2013;19:3207-16. [PMID: 23745022 DOI: 10.3748/wjg.v19.i21.3207] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
8 Kogiso T, Tokushige K. The Current View of Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma. Cancers (Basel) 2021;13:516. [PMID: 33572797 DOI: 10.3390/cancers13030516] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
9 Paternostro R, Sieghart W, Trauner M, Pinter M. Cancer and hepatic steatosis. ESMO Open 2021;6:100185. [PMID: 34139486 DOI: 10.1016/j.esmoop.2021.100185] [Reference Citation Analysis]
10 Muangpaisarn P, Jampoka K, Payungporn S, Wisedopas N, Bunchorntavakul C, Tangkijvanich P, Treeprasertsuk S. Serum microRNA-34a is potential biomarker for inflammation in nonalcoholic fatty liver disease. Asian Biomedicine 2017;10:163-71. [DOI: 10.5372/1905-7415.1002.478] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
11 European Association for Study of Liver. European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48:599-641. [PMID: 22424278 DOI: 10.1016/j.ejca.2011.12.021] [Cited by in Crossref: 273] [Cited by in F6Publishing: 250] [Article Influence: 30.3] [Reference Citation Analysis]
12 Demir M, Lang S, Steffen HM. Nonalcoholic fatty liver disease - current status and future directions. J Dig Dis 2015;16:541-57. [PMID: 26406351 DOI: 10.1111/1751-2980.12291] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 11.6] [Reference Citation Analysis]
13 Tiniakos DG, Maurício J, Reeves HL. Fatty Liver Disease and Hepatocellular Carcinoma: The Pathologist's View. Adv Exp Med Biol 2018;1032:55-69. [PMID: 30362090 DOI: 10.1007/978-3-319-98788-0_4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Gawrieh S, Dakhoul L, Miller E, Scanga A, deLemos A, Kettler C, Burney H, Liu H, Abu-Sbeih H, Chalasani N, Wattacheril J. Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study. Aliment Pharmacol Ther 2019;50:809-21. [PMID: 31475372 DOI: 10.1111/apt.15464] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 16.5] [Reference Citation Analysis]
15 Hashimoto E, Tokushige K, Ludwig J. Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges. Hepatol Res. 2015;45:20-28. [PMID: 24661406 DOI: 10.1111/hepr.12333] [Cited by in Crossref: 57] [Cited by in F6Publishing: 43] [Article Influence: 8.1] [Reference Citation Analysis]
16 Said A, Ghufran A. Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma. World J Clin Oncol 2017;8:429-36. [PMID: 29291167 DOI: 10.5306/wjco.v8.i6.429] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 42] [Article Influence: 12.8] [Reference Citation Analysis]
17 Duan XY, Zhang L, Fan JG, Qiao L. NAFLD leads to liver cancer: do we have sufficient evidence? Cancer Lett 2014;345:230-4. [PMID: 23941829 DOI: 10.1016/j.canlet.2013.07.033] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
18 Shetty K, Chen J, Shin JH, Jogunoori W, Mishra L. Pathogenesis of hepatocellular carcinoma development in non alcoholic fatty liver disease. Curr Hepatol Rep. 2015;14:119-127. [PMID: 26114083 DOI: 10.1007/s11901-015-0260-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
19 Kochi T, Shimizu M, Terakura D, Baba A, Ohno T, Kubota M, Shirakami Y, Tsurumi H, Tanaka T, Moriwaki H. Non-alcoholic steatohepatitis and preneoplastic lesions develop in the liver of obese and hypertensive rats: suppressing effects of EGCG on the development of liver lesions. Cancer Lett 2014;342:60-9. [PMID: 23981577 DOI: 10.1016/j.canlet.2013.08.031] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
20 Guo Y, Xiong Y, Sheng Q, Zhao S, Wattacheril J, Flynn CR. A micro-RNA expression signature for human NAFLD progression. J Gastroenterol. 2016;51:1022-1030. [PMID: 26874844 DOI: 10.1007/s00535-016-1178-0] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 9.4] [Reference Citation Analysis]
21 Lee SS, Jeong SH, Byoun YS, Chung SM, Seong MH, Sohn HR, Min BY, Jang ES, Kim JW, Park GJ. Clinical features and outcome of cryptogenic hepatocellular carcinoma compared to those of viral and alcoholic hepatocellular carcinoma. BMC Cancer. 2013;13:335. [PMID: 23829392 DOI: 10.1186/1471-2407-13-335] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
22 Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14:32-42. [PMID: 27729660 DOI: 10.1038/nrgastro.2016.147] [Cited by in Crossref: 329] [Cited by in F6Publishing: 275] [Article Influence: 65.8] [Reference Citation Analysis]
23 Brunt EM, Wong VW, Nobili V, Day CP, Sookoian S, Maher JJ, Bugianesi E, Sirlin CB, Neuschwander-tetri BA, Rinella ME. Nonalcoholic fatty liver disease. Nat Rev Dis Primers 2015;1. [DOI: 10.1038/nrdp.2015.80] [Cited by in Crossref: 302] [Cited by in F6Publishing: 258] [Article Influence: 50.3] [Reference Citation Analysis]
24 Tokushige K, Hyogo H, Nakajima T, Ono M, Kawaguchi T, Honda K, Eguchi Y, Nozaki Y, Kawanaka M, Tanaka S, Imajo K, Sumida Y, Kamada Y, Fujii H, Suzuki Y, Kogiso T, Karino Y, Munekage K, Kuromatsu R, Oeda S, Yanase M, Mori K, Ogawa Y, Seko Y, Takehara T, Itoh Y, Nakajima A, Kanemasa K, Nishino K, Masaki N, Takahashi H, Seike M, Torimura T, Saibara T, Toyota J, Chayama K, Hashimoto E. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey. J Gastroenterol 2016;51:586-96. [PMID: 26456168 DOI: 10.1007/s00535-015-1129-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
25 Ratziu V, Marchesini G. When the journey from obesity to cirrhosis takes an early start. Journal of Hepatology 2016;65:249-51. [DOI: 10.1016/j.jhep.2016.05.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
26 Jung YB, Yoo JE, Han DH, Kim KS, Choi JS, Kim DY, Park YN, Choi GH. Clinical and survival outcomes after hepatectomy in patients with non-alcoholic fatty liver and hepatitis B-related hepatocellular carcinoma. HPB (Oxford) 2021;23:1113-22. [PMID: 33309568 DOI: 10.1016/j.hpb.2020.10.027] [Reference Citation Analysis]
27 Chongmelaxme B, Phisalprapa P, Sawangjit R, Dilokthornsakul P, Chaiyakunapruk N. Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand. Pharmacoeconomics 2019;37:267-78. [PMID: 30430467 DOI: 10.1007/s40273-018-0736-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
28 Colditz GA, Peterson LL. Obesity and Cancer: Evidence, Impact, and Future Directions. Clinical Chemistry 2018;64:154-62. [DOI: 10.1373/clinchem.2017.277376] [Cited by in Crossref: 68] [Cited by in F6Publishing: 47] [Article Influence: 22.7] [Reference Citation Analysis]
29 Kawaguchi T, Sumida Y, Umemura A, Matsuo K, Takahashi M, Takamura T, Yasui K, Saibara T, Hashimoto E, Kawanaka M. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS One. 2012;7:e38322. [PMID: 22719876 DOI: 10.1371/journal.pone.0038322] [Cited by in Crossref: 171] [Cited by in F6Publishing: 155] [Article Influence: 19.0] [Reference Citation Analysis]
30 Kai K, Koga H, Aishima S, Kawaguchi A, Yamaji K, Ide T, Ueda J, Noshiro H. Impact of smoking habit on surgical outcomes in non-B non-C patients with curative resection for hepatocellular carcinoma. World J Gastroenterol. 2017;23:1397-1405. [PMID: 28293086 DOI: 10.3748/wjg.v23.i8.1397] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
31 Sakai H, Shirakami Y, Shimizu M. Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents. World J Gastroenterol 2016;22:394-406. [PMID: 26755885 DOI: 10.3748/wjg.v22.i1.394] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
32 Ueyama M, Nishida N, Korenaga M, Korenaga K, Kumagai E, Yanai H, Adachi H, Katsuyama H, Moriyama S, Hamasaki H. The impact of PNPLA3 and JAZF1 on hepatocellular carcinoma in non-viral hepatitis patients with type 2 diabetes mellitus. J Gastroenterol. 2016;51:370-379. [PMID: 26337813 DOI: 10.1007/s00535-015-1116-6] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
33 Gupta H, Youn GS, Shin MJ, Suk KT. Role of Gut Microbiota in Hepatocarcinogenesis. Microorganisms. 2019;7:pii: E121. [PMID: 31060311 DOI: 10.3390/microorganisms7050121] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 19.5] [Reference Citation Analysis]
34 Burra P, Bizzaro D, Gonta A, Shalaby S, Gambato M, Morelli MC, Trapani S, Floreani A, Marra F, Brunetto MR, Taliani G, Villa E; Special Interest Group Gender in Hepatology of the Italian Association for the Study of the Liver (AISF). Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Liver Int 2021;41:1713-33. [PMID: 33982400 DOI: 10.1111/liv.14943] [Reference Citation Analysis]
35 White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10:1342-1359.e2. [PMID: 23041539 DOI: 10.1016/j.cgh.2012.10.00] [Reference Citation Analysis]
36 European Association For The Study Of The Liver. European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943. [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001] [Cited by in Crossref: 3642] [Cited by in F6Publishing: 3260] [Article Influence: 404.7] [Reference Citation Analysis]
37 Reddy SK, Hyder O, Marsh JW, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, Pulitano C, Barroso E, Aldrighetti L. Prevalence of nonalcoholic steatohepatitis among patients with resectable intrahepatic cholangiocarcinoma. J Gastrointest Surg. 2013;17:748-755. [PMID: 23355033 DOI: 10.1007/s11605-013-2149-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
38 Baffy G. Hepatocellular Carcinoma in Obesity: Finding a Needle in the Haystack? In: Yu J, editor. Obesity, Fatty Liver and Liver Cancer. Singapore: Springer; 2018. pp. 63-77. [DOI: 10.1007/978-981-10-8684-7_6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
39 Anastasopoulos NT, Lianos GD, Tatsi V, Karampa A, Goussia A, Glantzounis GK. Clinical heterogeneity in patients with non-alcoholic fatty liver disease-associated hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2020;14:1025-33. [PMID: 32746645 DOI: 10.1080/17474124.2020.1802244] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
40 Kishida N, Matsuda S, Itano O, Shinoda M, Kitago M, Yagi H, Abe Y, Hibi T, Masugi Y, Aiura K, Sakamoto M, Kitagawa Y. Development of a novel mouse model of hepatocellular carcinoma with nonalcoholic steatohepatitis using a high-fat, choline-deficient diet and intraperitoneal injection of diethylnitrosamine. BMC Gastroenterol 2016;16:61. [PMID: 27296438 DOI: 10.1186/s12876-016-0477-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
41 Dhamija E, Paul SB, Kedia S. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern. Indian J Med Res. 2019;149:9-17. [PMID: 31115369 DOI: 10.4103/ijmr.ijmr_1456_17] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
42 White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10:1342-1359.e2. [PMID: 23041539 DOI: 10.1016/j.cgh.2012.10.001] [Cited by in Crossref: 413] [Cited by in F6Publishing: 369] [Article Influence: 45.9] [Reference Citation Analysis]
43 Kawaguchi T, Shima T, Mizuno M, Mitsumoto Y, Umemura A, Kanbara Y, Tanaka S, Sumida Y, Yasui K, Takahashi M. Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers. PLoS One. 2018;13:e0185490. [PMID: 29385134 DOI: 10.1371/journal.pone.0185490] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 14.7] [Reference Citation Analysis]
44 Perumpail RB, Wong RJ, Ahmed A, Harrison SA. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience. Dig Dis Sci. 2015;60:3142-3148. [PMID: 26250831 DOI: 10.1007/s10620-015-3821-7] [Cited by in Crossref: 63] [Cited by in F6Publishing: 54] [Article Influence: 10.5] [Reference Citation Analysis]
45 Federico A, Dallio M, Loguercio C. Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years. Molecules 2017;22:E191. [PMID: 28125040 DOI: 10.3390/molecules22020191] [Cited by in Crossref: 132] [Cited by in F6Publishing: 94] [Article Influence: 33.0] [Reference Citation Analysis]
46 Plaz Torres MC, Bodini G, Furnari M, Marabotto E, Zentilin P, Strazzabosco M, Giannini EG. Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? Cancers (Basel). 2020;12. [PMID: 32486355 DOI: 10.3390/cancers12061422] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
47 Massoud O, Charlton M. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma. Clinics in Liver Disease 2018;22:201-11. [DOI: 10.1016/j.cld.2017.08.014] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 11.7] [Reference Citation Analysis]
48 Shima T, Uto H, Ueki K, Takamura T, Kohgo Y, Kawata S, Yasui K, Park H, Nakamura N, Nakatou T, Tanaka N, Umemura A, Mizuno M, Tanaka J, Okanoue T. Clinicopathological features of liver injury in patients with type 2 diabetes mellitus and comparative study of histologically proven nonalcoholic fatty liver diseases with or without type 2 diabetes mellitus. J Gastroenterol 2013;48:515-25. [PMID: 22911170 DOI: 10.1007/s00535-012-0653-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
49 Oda K, Uto H, Mawatari S, Ido A. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies. Clin J Gastroenterol. 2015;8:1-9. [PMID: 25575848 DOI: 10.1007/s12328-014-0548-5] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
50 Golabi P, Rhea L, Henry L, Younossi ZM. Hepatocellular carcinoma and non-alcoholic fatty liver disease. Hepatol Int. 2019;13:688-694. [PMID: 31701393 DOI: 10.1007/s12072-019-09995-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
51 Arase Y, Shiraishi K, Anzai K, Sato H, Teramura E, Tsuruya K, Hirose S, Deguchi R, Toyoda M, Mine T, Kagawa T. Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Clin Drug Investig 2019;39:631-41. [PMID: 30993553 DOI: 10.1007/s40261-019-00785-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
52 Kumamoto R, Uto H, Oda K, Ibusuki R, Tanoue S, Arima S, Mawatari S, Kumagai K, Numata M, Tamai T, Moriuchi A, Fujita H, Oketani M, Ido A, Tsubouchi H. Dietary fructose enhances the incidence of precancerous hepatocytes induced by administration of diethylnitrosamine in rat. Eur J Med Res 2013;18:54. [PMID: 24321741 DOI: 10.1186/2047-783X-18-54] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
53 Hagström H, Kechagias S, Ekstedt M. Risk for hepatic and extra-hepatic outcomes in nonalcoholic fatty liver disease. J Intern Med 2021. [PMID: 34118091 DOI: 10.1111/joim.13343] [Reference Citation Analysis]
54 Wong VW, Chan WK, Chitturi S, Chawla Y, Dan YY, Duseja A, Fan J, Goh KL, Hamaguchi M, Hashimoto E, Kim SU, Lesmana LA, Lin YC, Liu CJ, Ni YH, Sollano J, Wong SK, Wong GL, Chan HL, Farrell G. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33:70-85. [PMID: 28670712 DOI: 10.1111/jgh.13857] [Cited by in Crossref: 165] [Cited by in F6Publishing: 134] [Article Influence: 82.5] [Reference Citation Analysis]
55 Lin BZ, Lin TJ, Lin CL, Liao LY, Chang TA, Lu BJ, Chen KY. Differentiation of clinical patterns and survival outcomes of hepatocellular carcinoma on hepatitis B and nonalcoholic fatty liver disease. J Chin Med Assoc 2021;84:606-13. [PMID: 33871391 DOI: 10.1097/JCMA.0000000000000530] [Reference Citation Analysis]
56 Xin YN, Geng N, Lin ZH, Cui YZ, Duan HP, Zhang M, Xuan SY. Serum complement C3f and fibrinopeptide A are potential novel diagnostic biomarkers for non-alcoholic fatty liver disease: a study in Qingdao Twins. PLoS One 2014;9:e108132. [PMID: 25250770 DOI: 10.1371/journal.pone.0108132] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
57 Liu H, Fu J, Hong R, Liu L, Li F. Acoustic Radiation Force Impulse Elastography for the Non-Invasive Evaluation of Hepatic Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review & Meta-Analysis. PLoS One. 2015;10:e0127782. [PMID: 26131717 DOI: 10.1371/journal.pone.0127782] [Cited by in Crossref: 64] [Cited by in F6Publishing: 52] [Article Influence: 10.7] [Reference Citation Analysis]
58 Kanda T, Goto T, Hirotsu Y, Masuzaki R, Moriyama M, Omata M. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E1525. [PMID: 32102237 DOI: 10.3390/ijms21041525] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 18.0] [Reference Citation Analysis]
59 Yasui K, Hashimoto E, Tokushige K, Koike K, Shima T, Kanbara Y, Saibara T, Uto H, Takami S, Kawanaka M. Clinical and pathological progression of non-alcoholic steatohepatitis to hepatocellular carcinoma. Hepatol Res. 2012;42:767-773. [PMID: 22487102 DOI: 10.1111/j.1872-034x.2012.00986.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
60 Tian Y, Wong VW, Chan HL, Cheng AS. Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease. Semin Cancer Biol. 2013;23:471-482. [PMID: 24018165 DOI: 10.1016/j.semcancer.2013.08.010] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 6.4] [Reference Citation Analysis]
61 Agosti P, Sabbà C, Mazzocca A. Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2018;1864:607-17. [DOI: 10.1016/j.bbadis.2017.11.026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 6.7] [Reference Citation Analysis]
62 Chen Y, Wang X, Wang J, Yan Z, Luo J. Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies. Eur J Cancer. 2012;48:2137-2145. [PMID: 22446023 DOI: 10.1016/j.ejca.2012.02.063] [Cited by in Crossref: 126] [Cited by in F6Publishing: 108] [Article Influence: 14.0] [Reference Citation Analysis]
63 Vanni E, Bugianesi E. Obesity and Liver Cancer. Clinics in Liver Disease 2014;18:191-203. [DOI: 10.1016/j.cld.2013.09.001] [Cited by in Crossref: 46] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
64 Kamada Y, Ono M, Hyogo H, Fujii H, Sumida Y, Yamada M, Mori K, Tanaka S, Maekawa T, Ebisutani Y, Yamamoto A, Takamatsu S, Yoneda M, Kawada N, Chayama K, Saibara T, Takehara T, Miyoshi E; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG‐NAFLD). Use of Mac-2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis. Hepatol Commun 2017;1:780-91. [PMID: 29404494 DOI: 10.1002/hep4.1080] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
65 Hashimoto E, Taniai M, Tokushige K. Characteristics and diagnosis of NAFLD/NASH. J Gastroenterol Hepatol. 2013;28 Suppl 4:64-70. [PMID: 24251707 DOI: 10.1111/jgh.12271] [Cited by in Crossref: 117] [Cited by in F6Publishing: 100] [Article Influence: 16.7] [Reference Citation Analysis]
66 Ching-Yeung Yu B, Kwok D, Wong VW. Magnitude of Nonalcoholic Fatty Liver Disease: Eastern Perspective. J Clin Exp Hepatol 2019;9:491-6. [PMID: 31516265 DOI: 10.1016/j.jceh.2019.01.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
67 Méndez-Sánchez N, Ridruejo E, Alves de Mattos A, Chávez-Tapia NC, Zapata R, Paraná R, Mastai R, Strauss E, Guevara-Casallas LG, Daruich J, Gadano A, Parise ER, Uribe M, Aguilar-Olivos NE, Dagher L, Ferraz-Neto BH, Valdés-Sánchez M, Sánchez-Avila JF. Latin American Association for the Study of the Liver (LAASL) clinical practice guidelines: management of hepatocellular carcinoma. Ann Hepatol 2014;13 Suppl 1:S4-40. [PMID: 24998696 [PMID: 24998696 DOI: 10.1016/s1665-2681(19)30919-6] [Cited by in Crossref: 17] [Article Influence: 2.8] [Reference Citation Analysis]
68 Serhal R, Hilal G, Boutros G, Sidaoui J, Wardi L, Ezzeddine S, Alaaeddine N. Nonalcoholic Steatohepatitis: Involvement of the Telomerase and Proinflammatory Mediators. Biomed Res Int 2015;2015:850246. [PMID: 26273651 DOI: 10.1155/2015/850246] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
69 Zeng F, Zhang Y, Han X, Zeng M, Gao Y, Weng J. Predicting Non-Alcoholic Fatty Liver Disease Progression and Immune Deregulations by Specific Gene Expression Patterns. Front Immunol 2020;11:609900. [PMID: 33574818 DOI: 10.3389/fimmu.2020.609900] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Siriwardana RC, Niriella MA, Dassanayake A, Ediriweera D, Gunetilleke B, Sivasundaram T, de Silva J. Association of Serum Ferritin with Diabetes and Alcohol in Patients with Non-Viral Liver Disease-Related Hepatocellular Carcinoma. Liver Cancer 2017;6:307-12. [PMID: 29234634 DOI: 10.1159/000477266] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
71 Kondo R, Nakashima O, Sata M, Imazeki F, Yokosuka O, Tanikawa K, Kage M, Yano H; Liver Cancer Study Group of Kyushu. Pathological characteristics of patients who develop hepatocellular carcinoma with negative results of both serous hepatitis B surface antigen and hepatitis C virus antibody. Hepatol Res. 2014;44:1039-1046. [PMID: 23937266 DOI: 10.1111/hepr.12219] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
72 Dongiovanni P, Romeo S, Valenti L. Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors. World J Gastroenterol 2014;20:12945-55. [PMID: 25278690 DOI: 10.3748/wjg.v20.i36.12945] [Cited by in CrossRef: 82] [Cited by in F6Publishing: 64] [Article Influence: 13.7] [Reference Citation Analysis]
73 Calzadilla Bertot L, Adams LA. The Natural Course of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci. 2016;17. [PMID: 27213358 DOI: 10.3390/ijms17050774] [Cited by in Crossref: 248] [Cited by in F6Publishing: 215] [Article Influence: 49.6] [Reference Citation Analysis]
74 Xia MF, Bian H, Gao X. NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD Treatment. Front Pharmacol. 2019;10:877. [PMID: 31447675 DOI: 10.3389/fphar.2019.00877] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 14.0] [Reference Citation Analysis]
75 Sekiba K, Otsuka M, Koike K. Potential of HBx Gene for Hepatocarcinogenesis in Noncirrhotic Liver. Semin Liver Dis 2021;41:142-9. [PMID: 33984871 DOI: 10.1055/s-0041-1723033] [Reference Citation Analysis]
76 Vonghia L, Michielsen P, Francque S. Immunological mechanisms in the pathophysiology of non-alcoholic steatohepatitis. Int J Mol Sci. 2013;14:19867-19890. [PMID: 24084730 DOI: 10.3390/ijms141019867] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 5.4] [Reference Citation Analysis]
77 Jun TW, Yeh ML, Yang JD, Chen VL, Nguyen P, Giama NH, Huang CF, Hsing AW, Dai CY, Huang JF, Chuang WL, Roberts LR, Yu ML, Nguyen MH. More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma. Liver Int 2018;38:895-902. [PMID: 29045023 DOI: 10.1111/liv.13613] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
78 Mencin AA, Loomba R, Lavine JE. Caring for children with NAFLD and navigating their care into adulthood. Nat Rev Gastroenterol Hepatol 2015;12:617-28. [PMID: 26323878 DOI: 10.1038/nrgastro.2015.146] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
79 Lam L, Fontaine H, Bourliere M, Lusivika-Nzinga C, Dorival C, Thabut D, Zoulim F, Habersetzer F, Asselah T, Duclos-Vallee JC, Bronowicki JP, Mathurin P, Decaens T, Ganne N, Guyader D, Leroy V, Rosa I, De Ledinghen V, Cales P, Causse X, Larrey D, Chazouilleres O, Gelu-Simeon M, Loustaud-Ratti V, Metivier S, Alric L, Riachi G, Gournay J, Minello A, Tran A, Geist C, Abergel A, Raffi F, D'Alteroche L, Portal I, Lapidus N, Pol S, Carrat F; ANRS/AFEF Hepather study group. Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort study. Clin Res Hepatol Gastroenterol 2021;45:101713. [PMID: 33930591 DOI: 10.1016/j.clinre.2021.101713] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
80 Kwok R, Tse YK, Wong GL, Ha Y, Lee AU, Ngu MC, Chan HL, Wong VW. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther. 2014;39:254-269. [PMID: 24308774 DOI: 10.1111/apt.12569] [Cited by in Crossref: 228] [Cited by in F6Publishing: 191] [Article Influence: 28.5] [Reference Citation Analysis]
81 Sadler EM, Mehta N, Bhat M, Ghanekar A, Greig PD, Grant DR, Yao F, Sapisochin G. Liver Transplantation for NASH-Related Hepatocellular Carcinoma Versus Non-NASH Etiologies of Hepatocellular Carcinoma. Transplantation. 2018;102:640-647. [PMID: 29319620 DOI: 10.1097/tp.0000000000002043] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 6.7] [Reference Citation Analysis]
82 Pais R, Fartoux L, Goumard C, Scatton O, Wendum D, Rosmorduc O, Ratziu V. Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period. Aliment Pharmacol Ther 2017;46:856-63. [PMID: 28857208 DOI: 10.1111/apt.14261] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 10.8] [Reference Citation Analysis]
83 Okuda Y, Mizuno S, Shiraishi T, Murata Y, Tanemura A, Azumi Y, Kuriyama N, Kishiwada M, Usui M, Sakurai H, Tabata M, Yamada T, Isaji S. Clinicopathological factors affecting survival and recurrence after initial hepatectomy in non-B non-C hepatocellular carcinoma patients with comparison to hepatitis B or C virus. Biomed Res Int 2014;2014:975380. [PMID: 24745029 DOI: 10.1155/2014/975380] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
84 Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Lonardo A. NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk. Adv Ther. 2017;34:1291-1326. [PMID: 28526997 DOI: 10.1007/s12325-017-0556-1] [Cited by in Crossref: 197] [Cited by in F6Publishing: 160] [Article Influence: 49.3] [Reference Citation Analysis]
85 Merchante N, Rodríguez-Fernández M, Pineda JA. Screening for Hepatocellular Carcinoma in HIV-Infected Patients: Current Evidence and Controversies. Curr HIV/AIDS Rep 2020;17:6-17. [PMID: 31933273 DOI: 10.1007/s11904-019-00475-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
86 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-23. [DOI: 10.1002/hep.25762] [Cited by in Crossref: 2057] [Cited by in F6Publishing: 1761] [Article Influence: 228.6] [Reference Citation Analysis]
87 Sumida Y, Yoneda M, Seko Y, Ishiba H, Hara T, Toyoda H, Yasuda S, Kumada T, Hayashi H, Kobayashi T, Imajo K, Yoneda M, Tada T, Kawaguchi T, Eguchi Y, Oeda S, Takahashi H, Tomita E, Okanoue T, Nakajima A, Japan Study Group Of Nafld Jsg-Nafld. Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Diagnostics (Basel) 2020;10:E579. [PMID: 32785100 DOI: 10.3390/diagnostics10080579] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
88 O'Byrne SN, Scott JW, Pilotte JR, Santiago ADS, Langendorf CG, Oakhill JS, Eduful BJ, Couñago RM, Wells CI, Zuercher WJ, Willson TM, Drewry DH. In Depth Analysis of Kinase Cross Screening Data to Identify CAMKK2 Inhibitory Scaffolds. Molecules 2020;25:E325. [PMID: 31941153 DOI: 10.3390/molecules25020325] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 11.0] [Reference Citation Analysis]
89 Tobari M, Hashimoto E. Characteristic Features of Nonalcoholic Fatty Liver Disease in Japan with a Focus on the Roles of Age, Sex and Body Mass Index. Gut Liver 2020;14:537-45. [PMID: 31887811 DOI: 10.5009/gnl19236] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
90 Greco A, De Masi R, Orlando S, Metrangolo A, Zecca V, Morciano G, De Donno A, Bagordo F, Piccinni G. Metastases of Hepatocellular Carcinoma Misdiagnosed as Isolated Hypertrophic Cardiomyopathy. Ann Hepatol 2017;16:966-9. [PMID: 29055932 DOI: 10.5604/01.3001.0010.5289] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
91 Mikolasevic I, Filipec-Kanizaj T, Mijic M, Jakopcic I, Milic S, Hrstic I, Sobocan N, Stimac D, Burra P. Nonalcoholic fatty liver disease and liver transplantation - Where do we stand? World J Gastroenterol. 2018;24:1491-1506. [PMID: 29662288 DOI: 10.3748/wjg.v24.i14.1491] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 37] [Article Influence: 15.7] [Reference Citation Analysis]
92 Xu H, Kong W, Liu L, Chi X, Wang X, Wu R, Gao X, Wang H, Qu L, Qi Y, Pan Y, Niu J. Accuracy of M2BPGi, compared with Fibro Scan®, in analysis of liver fibrosis in patients with hepatitis C. BMC Gastroenterol 2017;17:62. [PMID: 28486931 DOI: 10.1186/s12876-017-0618-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
93 Rowe IA, Wong VW, Loomba R. Treatment Candidacy for Pharmacologic Therapies for NASH. Clinical Gastroenterology and Hepatology 2021. [DOI: 10.1016/j.cgh.2021.03.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
94 Baffy G. Allostasis in nonalcoholic fatty liver disease: implications for risk assessment. Dig Dis Sci 2013;58:302-8. [PMID: 22886595 DOI: 10.1007/s10620-012-2344-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
95 Kang SY, Kim YJ, Park HS. Trends in the Prevalence of Non-Alcoholic Fatty Liver Disease and Its Future Predictions in Korean Men, 1998-2035. J Clin Med 2020;9:E2626. [PMID: 32823604 DOI: 10.3390/jcm9082626] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
96 Reid DT, Eksteen B. Murine models provide insight to the development of non-alcoholic fatty liver disease. Nutr Res Rev. 2015;28:133-142. [PMID: 26494024 DOI: 10.1017/s0954422415000128] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
97 Wong S, Chan W. Epidemiology of non-alcoholic fatty liver disease in Asia. Indian J Gastroenterol 2020;39:1-8. [DOI: 10.1007/s12664-020-01018-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
98 Matsui T, Hamada-Tsutsumi S, Naito Y, Nojima M, Iio E, Tamori A, Kubo S, Ide T, Kondo Y, Eguchi Y, Komori A, Morine Y, Shimada M, Utsunomiya T, Shirabe K, Kimura K, Hiasa Y, Chuaypen N, Tangkijvanich P, Naiki-Ito A, Takahashi S, Ochiya T, Tanaka Y. Identification of microRNA-96-5p as a postoperative, prognostic microRNA predictor in nonviral hepatocellular carcinoma. Hepatol Res 2021. [PMID: 34038612 DOI: 10.1111/hepr.13674] [Reference Citation Analysis]
99 Tanaka S, Miyanishi K, Kobune M, Kawano Y, Hoki T, Kubo T, Hayashi T, Sato T, Sato Y, Takimoto R. Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. J Gastroenterol. 2013;48:1249-1258. [PMID: 23329365 DOI: 10.1007/s00535-012-0739-0] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
100 Cai J, Zhang XJ, Li H. Progress and challenges in the prevention and control of nonalcoholic fatty liver disease. Med Res Rev. 2019;39:328-348. [PMID: 29846945 DOI: 10.1002/med.21515] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 12.0] [Reference Citation Analysis]
101 Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012;56:1384-91. [PMID: 22326465 DOI: 10.1016/j.jhep.2011.10.027] [Cited by in Crossref: 536] [Cited by in F6Publishing: 484] [Article Influence: 59.6] [Reference Citation Analysis]
102 Meredith I, Sarfati D, Ikeda T, Blakely T. Cancer in Pacific people in New Zealand. Cancer Causes Control 2012;23:1173-84. [PMID: 22618362 DOI: 10.1007/s10552-012-9986-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
103 Kim HS, El-Serag HB. The Epidemiology of Hepatocellular Carcinoma in the USA. Curr Gastroenterol Rep. 2019;21:17. [PMID: 30976932 DOI: 10.1007/s11894-019-0681-x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 18.5] [Reference Citation Analysis]
104 German MN, Lutz MK, Pickhardt PJ, Bruce RJ, Said A. Statin Use is Protective Against Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Case-control Study. Journal of Clinical Gastroenterology 2020;54:733-40. [DOI: 10.1097/mcg.0000000000001260] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 5.5] [Reference Citation Analysis]
105 Aleksandrova K, Stelmach-Mardas M, Schlesinger S. Obesity and Liver Cancer. Recent Results Cancer Res 2016;208:177-98. [PMID: 27909908 DOI: 10.1007/978-3-319-42542-9_10] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
106 Fujiwara N, Qian T, Koneru B, Hoshida Y. Omics-derived hepatocellular carcinoma risk biomarkers for precision care of chronic liver diseases. Hepatol Res 2020;50:817-30. [PMID: 32323426 DOI: 10.1111/hepr.13506] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
107 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ;  American Gastroenterological Association;  American Association for the Study of Liver Diseases;  American College of Gastroenterologyh. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592-1609. [PMID: 22656328 DOI: 10.1053/j.gastro.2012.04.001] [Cited by in Crossref: 1078] [Cited by in F6Publishing: 947] [Article Influence: 119.8] [Reference Citation Analysis]
108 Hardy T, Anstee QM, Day CP. Nonalcoholic fatty liver disease: new treatments. Curr Opin Gastroenterol. 2015;31:175-183. [PMID: 25774446 DOI: 10.1097/mog.0000000000000175] [Cited by in Crossref: 61] [Cited by in F6Publishing: 30] [Article Influence: 12.2] [Reference Citation Analysis]
109 Esfeh JM, Hajifathalian K, Ansari-Gilani K. Sensitivity of ultrasound in detecting hepatocellular carcinoma in obese patients compared to explant pathology as the gold standard. Clin Mol Hepatol. 2020;26:54-59. [PMID: 31726817 DOI: 10.3350/cmh.2019.0039] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
110 Tobari M, Hashimoto E, Taniai M, Kodama K, Kogiso T, Tokushige K, Yamamoto M, Takayoshi N, Satoshi K, Tatsuo A. The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis. J Gastroenterol Hepatol. 2020;35:862-869. [PMID: 31597206 DOI: 10.1111/jgh.14867] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
111 Reddy SK, Steel JL, Chen H, Demateo DJ, Cardinal J, Behari J, Humar A, Marsh JW, Geller DA, Tsung A. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology 2012;55:1809-19. [DOI: 10.1002/hep.25536] [Cited by in Crossref: 124] [Cited by in F6Publishing: 108] [Article Influence: 13.8] [Reference Citation Analysis]
112 Negro F. Natural history of NASH and HCC. Liver Int 2020;40:72-6. [DOI: 10.1111/liv.14362] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 26.0] [Reference Citation Analysis]
113 Tokushige K, Hashimoto E, Kodama K. Hepatocarcinogenesis in non-alcoholic fatty liver disease in Japan. J Gastroenterol Hepatol. 2013;28 Suppl 4:88-92. [PMID: 24251711 DOI: 10.1111/jgh.12239] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
114 Fan J, Kim S, Wong VW. New trends on obesity and NAFLD in Asia. Journal of Hepatology 2017;67:862-73. [DOI: 10.1016/j.jhep.2017.06.003] [Cited by in Crossref: 348] [Cited by in F6Publishing: 304] [Article Influence: 87.0] [Reference Citation Analysis]
115 Hoki T, Katsuta E, Yan L, Takabe K, Ito F. Low DMT1 Expression Associates With Increased Oxidative Phosphorylation and Early Recurrence in Hepatocellular Carcinoma. J Surg Res 2019;234:343-52. [PMID: 30527495 DOI: 10.1016/j.jss.2018.11.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
116 Zoller H, Tilg H. Nonalcoholic fatty liver disease and hepatocellular carcinoma. Metabolism 2016;65:1151-60. [DOI: 10.1016/j.metabol.2016.01.010] [Cited by in Crossref: 84] [Cited by in F6Publishing: 81] [Article Influence: 16.8] [Reference Citation Analysis]
117 Mun J, Kim S, Yoon HG, You Y, Kim OK, Choi KC, Lee YH, Lee J, Park J, Jun W. Water Extract of Curcuma longa L. Ameliorates Non-Alcoholic Fatty Liver Disease. Nutrients 2019;11:E2536. [PMID: 31640183 DOI: 10.3390/nu11102536] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
118 Seki K, Shima T, Oya H, Mitsumoto Y, Mizuno M, Okanoue T. Assessment of transient elastography in Japanese patients with non-alcoholic fatty liver disease. Hepatol Res 2017;47:882-9. [PMID: 27753194 DOI: 10.1111/hepr.12829] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
119 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ; American Association for the Study of Liver Diseases; American College of Gastroenterology; American Gastroenterological Association. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012;107:811-826. [PMID: 22641309 DOI: 10.1038/ajg.2012.128] [Cited by in Crossref: 245] [Cited by in F6Publishing: 218] [Article Influence: 27.2] [Reference Citation Analysis]
120 Jafri W, Kamran M. Hepatocellular Carcinoma in Asia: A Challenging Situation. Euroasian J Hepatogastroenterol 2019;9:27-33. [PMID: 31988864 DOI: 10.5005/jp-journals-10018-1292] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
121 Zelber-Sagi S, Lotan R, Shlomai A, Webb M, Harrari G, Buch A, Nitzan Kaluski D, Halpern Z, Oren R. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol. 2012;56:1145-1151. [PMID: 22245895 DOI: 10.1016/j.jhep.2011.12.011] [Cited by in Crossref: 148] [Cited by in F6Publishing: 127] [Article Influence: 16.4] [Reference Citation Analysis]
122 Mahady SE, Adams LA. Burden of non-alcoholic fatty liver disease in Australia: Burden of fatty liver in Australia. Journal of Gastroenterology and Hepatology 2018;33:1-11. [DOI: 10.1111/jgh.14270] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
123 Khare T, Khare S, Angdisen JJ, Zhang Q, Stuckel A, Mooney BP, Ridenhour SE, Gitan RS, Hammoud GM, Ibdah JA. Defects in long-chain 3-hydroxy acyl-CoA dehydrogenase lead to hepatocellular carcinoma: A novel etiology of hepatocellular carcinoma. Int J Cancer 2020;147:1461-73. [PMID: 32115688 DOI: 10.1002/ijc.32943] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
124 Schwarze V, Marschner C, Völckers W, de Figueiredo GN, Rübenthaler J, Clevert DA. The diagnostic performance of contrast-enhanced ultrasound (CEUS) for evaluating hepatocellular carcinoma (HCC) juxtaposed to MRI findings; a retrospective single-center analysis of 292 patients. Clin Hemorheol Microcirc 2020;76:155-60. [PMID: 32925017 DOI: 10.3233/CH-209213] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
125 Marengo A, Jouness RI, Bugianesi E. Progression and Natural History of Nonalcoholic Fatty Liver Disease in Adults. Clin Liver Dis 2016;20:313-24. [PMID: 27063271 DOI: 10.1016/j.cld.2015.10.010] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 10.8] [Reference Citation Analysis]
126 Gerbes A, Zoulim F, Tilg H, Dufour JF, Bruix J, Paradis V, Salem R, Peck-Radosavljevic M, Galle PR, Greten TF. Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma. Gut. 2018;67:380-388. [PMID: 29150490 DOI: 10.1136/gutjnl-2017-315068] [Cited by in Crossref: 82] [Cited by in F6Publishing: 77] [Article Influence: 20.5] [Reference Citation Analysis]
127 Schwarze V, Marschner C, Völckers W, Grosu S, Negrão de Figueiredo G, Rübenthaler J, Clevert DA. Diagnostic value of contrast-enhanced ultrasound versus computed tomography for hepatocellular carcinoma: a retrospective, single-center evaluation of 234 patients. J Int Med Res 2020;48:300060520930151. [PMID: 32529869 DOI: 10.1177/0300060520930151] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
128 Mattos ÂZ, Debes JD, Dhanasekaran R, Benhammou JN, Arrese M, Patrício ALV, Zilio AC, Mattos AA. Hepatocellular carcinoma in nonalcoholic fatty liver disease: A growing challenge. WJH 2021;13:1107-21. [DOI: 10.4254/wjh.v13.i9.1107] [Reference Citation Analysis]
129 Tiniakos DG, Anstee QM, Burt AD. Fatty Liver Disease. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 308-71. [DOI: 10.1016/b978-0-7020-6697-9.00005-4] [Cited by in Crossref: 7] [Article Influence: 2.3] [Reference Citation Analysis]
130 Ge J, Bai Y, Tang B, Wei D, Yan M. The Gene Signature Associated with Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. J Oncol 2021;2021:6630535. [PMID: 33868403 DOI: 10.1155/2021/6630535] [Reference Citation Analysis]
131 Yamada R, Hiramatsu N, Oze T, Urabe A, Tahata Y, Morishita N, Kodama T, Hikita H, Sakamori R, Yakushijin T, Yamada A, Hagiwara H, Mita E, Oshita M, Itoh T, Fukui H, Inui Y, Hijioka T, Inada M, Katayama K, Tamura S, Inoue A, Imai Y, Tatsumi T, Hamasaki T, Hayashi N, Takehara T. Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C virus infection who achieved sustained virologic response. Hepatol Res. 2019;49:570-578. [PMID: 30623521 DOI: 10.1111/hepr.13310] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
132 El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology. 2014;60:1767-1775. [PMID: 24839253 DOI: 10.1002/hep.27222] [Cited by in Crossref: 380] [Cited by in F6Publishing: 329] [Article Influence: 54.3] [Reference Citation Analysis]
133 Al-sharhan F, Dohan A, Barat M, Feddal A, Terris B, Pol S, Mallet V, Soyer P. MRI presentation of hepatocellular carcinoma in non-alcoholic steatohepatitis (NASH). European Journal of Radiology 2019;119:108648. [DOI: 10.1016/j.ejrad.2019.108648] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
134 Wong RJ, Ahmed A. Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations. World J Hepatol. 2014;6:263-273. [PMID: 24868320 DOI: 10.4254/wjh.v6.i5.263] [Cited by in Crossref: 74] [Cited by in F6Publishing: 54] [Article Influence: 10.6] [Reference Citation Analysis]
135 Vanni E, Mezzabotta L, Bugianesi E. NAFLD and Hepatocellular Carcinoma: How Big a Problem is This Really? Curr Hepatology Rep 2014;13:113-8. [DOI: 10.1007/s11901-014-0225-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
136 Goh GB, Chang PE, Tan CK. Changing epidemiology of hepatocellular carcinoma in Asia. Best Pract Res Clin Gastroenterol. 2015;29:919-928. [PMID: 26651253 DOI: 10.1016/j.bpg.2015.09.007] [Cited by in Crossref: 74] [Cited by in F6Publishing: 75] [Article Influence: 12.3] [Reference Citation Analysis]
137 Thompson SM, Garg I, Ehman EC, Sheedy SP, Bookwalter CA, Carter RE, Roberts LR, Venkatesh SK. Non-alcoholic fatty liver disease-associated hepatocellular carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at MRI. Br J Radiol 2018;91:20180345. [PMID: 30074820 DOI: 10.1259/bjr.20180345] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
138 Phan J, Ng V, Sheinbaum A, French S, Choi G, El Kabany M, Durazo F, Saab S, Tong M, Busuttil R, Han SH. Hyperlipidemia and Nonalcoholic Steatohepatitis Predispose to Hepatocellular Carcinoma Development Without Cirrhosis. J Clin Gastroenterol. 2019;53:309-313. [PMID: 29912756 DOI: 10.1097/mcg.0000000000001062] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
139 Sasdelli AS, Brodosi L, Marchesini G. NAFLD-Associated Hepatocellular Carcinoma: a Threat to Patients with Metabolic Disorders. Curr Hepatology Rep 2016;15:103-12. [DOI: 10.1007/s11901-016-0297-7] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
140 Van Herck MA, Weyler J, Kwanten WJ, Dirinck EL, De Winter BY, Francque SM, Vonghia L. The Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obesity. Front Immunol 2019;10:82. [PMID: 30787925 DOI: 10.3389/fimmu.2019.00082] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 24.5] [Reference Citation Analysis]
141 Takahashi Y, Watabe S, Togashi-Kumagai A, Watanabe M, Dungubat E, Kusano H, Kobayashi Y, Harada N, Yamaji R, Sugimoto K, Fukusato T. Effects of low ethanol consumption on nonalcoholic steatohepatitis in mice. Alcohol 2020;87:51-61. [PMID: 32553943 DOI: 10.1016/j.alcohol.2020.04.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
142 Moriya A, Iwasaki Y, Ohguchi S, Kayashima E, Mitsumune T, Taniguchi H, Ando M, Yamamoto K. Roles of alcohol consumption in fatty liver: A longitudinal study. Journal of Hepatology 2015;62:921-7. [DOI: 10.1016/j.jhep.2014.11.025] [Cited by in Crossref: 59] [Cited by in F6Publishing: 48] [Article Influence: 9.8] [Reference Citation Analysis]
143 Kolly P, Dufour JF. Surveillance for Hepatocellular Carcinoma in Patients with NASH. Diagnostics (Basel). 2016;6. pii:E22. [PMID: 27338480 DOI: 10.3390/diagnostics6020022] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
144 Aller R, Fernández-Rodríguez C, Lo Iacono O, Bañares R, Abad J, Carrión JA, García-Monzón C, Caballería J, Berenguer M, Rodríguez-Perálvarez M, Miranda JL, Vilar-Gómez E, Crespo J, García-Cortés M, Reig M, Navarro JM, Gallego R, Genescà J, Arias-Loste MT, Pareja MJ, Albillos A, Muntané J, Jorquera F, Solà E, Hernández-Guerra M, Rojo MÁ, Salmerón J, Caballería L, Diago M, Molina E, Bataller R, Romero-Gómez M. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. Gastroenterol Hepatol 2018;41:328-49. [PMID: 29631866 DOI: 10.1016/j.gastrohep.2017.12.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 7.7] [Reference Citation Analysis]
145 El‐serag HB. Epidemiology of Hepatocellular Carcinoma. In: Arias IM, Alter HJ, Boyer JL, Cohen DE, Shafritz DA, Thorgeirsson SS, Wolkoff AW, editors. The Liver. Wiley; 2020. pp. 758-72. [DOI: 10.1002/9781119436812.ch59] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 14.0] [Reference Citation Analysis]
146 El-Serag HB, Kanwal F. Obesity and hepatocellular carcinoma: hype and reality. Hepatology 2014;60:779-81. [PMID: 24753107 DOI: 10.1002/hep.27172] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
147 Munteanu MA, Mircea PA. From NAFLD to Cardiovascular Disease. Is it (Still) the Metabolic Syndrome? Clujul Med 2014;87:80-6. [PMID: 26528002 DOI: 10.15386/cjmed-277] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
148 Liu Y, Li H, Ye N, Luo CJ, Hu YY, Wu H, Gong JP. Non-Cirrhotic Liver is Associated with Poor Prognosis of Hepatocellular Carcinoma: A Literature Review. Med Sci Monit 2019;25:6615-23. [PMID: 31479436 DOI: 10.12659/MSM.915722] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
149 Bhala N, George J. The Burden of Non-alcoholic Fatty Liver Disease (NAFLD) in the Asia Pacific Region. Curr Hepatology Rep 2015;14:77-86. [DOI: 10.1007/s11901-015-0264-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
150 Hung HH, Chao Y, Chiou YY, Li CP, Lee RC, Huo TI, Huang YH, Chau GY, Su CW, Yeh YC, Lin HC, Lee SD, Wu JC. A comparison of clinical manifestations and prognoses between patients with hepatocellular carcinoma and Child-Pugh scores of 5 or 6. Medicine (Baltimore) 2014;93:e348. [PMID: 25546689 DOI: 10.1097/MD.0000000000000348] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
151 Chitturi S, Wong VW, Chan WK, Wong GL, Wong SK, Sollano J, Ni YH, Liu CJ, Lin YC, Lesmana LA. The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups. J Gastroenterol Hepatol. 2018;33:86-98. [PMID: 28692197 DOI: 10.1111/jgh.13856] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 27.5] [Reference Citation Analysis]
152 Bertot LC, Adams LA. Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2019;13:179-87. [PMID: 30791782 DOI: 10.1080/17474124.2019.1549989] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
153 Li Q, Li WW, Yang X, Fan WB, Yu JH, Xie SS, Liu L, Ma LX, Chen SJ, Kato N. Type 2 diabetes and hepatocellular carcinoma: a case-control study in patients with chronic hepatitis B. Int J Cancer. 2012;131:1197-1202. [PMID: 22052244 DOI: 10.1002/ijc.27337] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
154 Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017;49:197-211. [PMID: 28303724 DOI: 10.1080/03602532.2017.1293683] [Cited by in Crossref: 137] [Cited by in F6Publishing: 114] [Article Influence: 34.3] [Reference Citation Analysis]
155 Koyama N, Yamazaki T, Kanetsuki Y, Hirota J, Asai T, Mitsumoto Y, Mizuno M, Shima T, Kanbara Y, Arai S. Activation of apoptosis inhibitor of macrophage is a sensitive diagnostic marker for NASH-associated hepatocellular carcinoma. J Gastroenterol. 2018;53:770-779. [PMID: 29086016 DOI: 10.1007/s00535-017-1398-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
156 Daugherity EK, Balmus G, Al Saei A, Moore ES, Abi Abdallah D, Rogers AB, Weiss RS, Maurer KJ. The DNA damage checkpoint protein ATM promotes hepatocellular apoptosis and fibrosis in a mouse model of non-alcoholic fatty liver disease. Cell Cycle. 2012;11:1918-1928. [PMID: 22544329 DOI: 10.4161/cc.20259] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 4.3] [Reference Citation Analysis]
157 Jackson TW, Ryherd GL, Scheibly CM, Sasser AL, Guillette TC, Belcher SM. Gestational Cd Exposure in the CD-1 Mouse Induces Sex-Specific Hepatic Insulin Insensitivity, Obesity, and Metabolic Syndrome in Adult Female Offspring. Toxicol Sci 2020;178:264-80. [PMID: 33259630 DOI: 10.1093/toxsci/kfaa154] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
158 Bello HR, Mahdi ZK, Lui SK, Nandwana SB, Harri PA, Davarpanah AH. Hepatocellular Carcinoma With Atypical Imaging Features: Review of the Morphologic Hepatocellular Carcinoma Subtypes With Radiology-Pathology Correlation. J Magn Reson Imaging 2021. [PMID: 33682266 DOI: 10.1002/jmri.27553] [Reference Citation Analysis]
159 Safcak D, Drazilova S, Gazda J, Andrasina I, Adamcova-Selcanova S, Barila R, Mego M, Rac M, Skladany L, Zigrai M, Janicko M, Jarcuska P. Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: Clinical Patterns, Outcomes, and Prognostic Factors for Overall Survival-A Retrospective Analysis of a Slovak Cohort. J Clin Med 2021;10:3186. [PMID: 34300352 DOI: 10.3390/jcm10143186] [Reference Citation Analysis]
160 Hassan I, Gane E. Improving survival in patients with hepatocellular carcinoma related to chronic hepatitis C and B but not in those related to non-alcoholic steatohepatitis or alcoholic liver disease: a 20-year experience from a national programme. Intern Med J 2019;49:1405-11. [PMID: 30908822 DOI: 10.1111/imj.14304] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
161 Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.Nat Rev Gastroenterol Hepatol. 2021;18:223-238. [PMID: 33349658 DOI: 10.1038/s41575-020-00381-6] [Cited by in Crossref: 49] [Cited by in F6Publishing: 25] [Article Influence: 49.0] [Reference Citation Analysis]
162 Jacobsen MC, Thrower SL, Ger RB, Leng S, Court LE, Brock KK, Tamm EP, Cressman ENK, Cody DD, Layman RR. Multi-energy computed tomography and material quantification: Current barriers and opportunities for advancement. Med Phys 2020;47:3752-71. [PMID: 32453879 DOI: 10.1002/mp.14241] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
163 Vongsuvanh R, van der Poorten D, George J. Non-alcoholic fatty liver disease-related hepatocellular carcinoma: a sleeping tiger in the Asia Pacific. Hepatol Int 2013;7 Suppl 2:823-32. [PMID: 26202297 DOI: 10.1007/s12072-013-9453-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
164 Mikolasevic I, Lukenda Zanko V, Jakopcic I, Domislovic V, Mijic A, Stevanovic T, Delija B, Bokun T, Dinjar Kujundzic P, Ostojic A, Filipec Kanizaj T, Grgurevic I, Krznaric Z, Stimac D, Targher G. Prospective evaluation of non-alcoholic fatty liver disease by elastographic methods of liver steatosis and fibrosis; controlled attenuation parameter and liver stiffness measurements. J Diabetes Complications 2020;34:107512. [PMID: 31882273 DOI: 10.1016/j.jdiacomp.2019.107512] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
165 Barat M, Nguyen TTL, Hollande C, Coty JB, Hoeffel C, Terris B, Dohan A, Mallet V, Pol S, Soyer P. LI-RADS v2018 major criteria: Do hepatocellular carcinomas in non-alcoholic steatohepatitis differ from those in virus-induced chronic liver disease on MRI? Eur J Radiol 2021;138:109651. [PMID: 33740627 DOI: 10.1016/j.ejrad.2021.109651] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
166 Gounder PP, Bulkow LR, Snowball M, Negus S, Spradling PR, Simons BC, McMahon BJ. Nested case-control study: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance. Aliment Pharmacol Ther 2016;43:1197-207. [PMID: 27061300 DOI: 10.1111/apt.13621] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
167 Okanoue T, Yasui K, Itoh Y. Non-Alcoholic Fatty Liver Disease in Japan. In: Farrell GC, Mccullough AJ, Day CP, editors. Non-Alcoholic Fatty Liver Disease. Oxford: Wiley-Blackwell; 2013. pp. 217-27. [DOI: 10.1002/9781118556153.ch19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
168 Williams KH, Shackel NA, Gorrell MD, McLennan SV, Twigg SM. Diabetes and nonalcoholic Fatty liver disease: a pathogenic duo. Endocr Rev. 2013;34:84-129. [PMID: 23238855 DOI: 10.1210/er.2012-1009] [Cited by in Crossref: 132] [Cited by in F6Publishing: 118] [Article Influence: 14.7] [Reference Citation Analysis]
169 Torres DM, Williams CD, Harrison SA. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2012;10:837-58. [PMID: 22446927 DOI: 10.1016/j.cgh.2012.03.011] [Cited by in Crossref: 156] [Cited by in F6Publishing: 137] [Article Influence: 17.3] [Reference Citation Analysis]
170 Pascual S, Herrera I, Irurzun J. New advances in hepatocellular carcinoma. World J Hepatol. 2016;8:421-438. [PMID: 27028578 DOI: 10.4254/wjh.v8.i9.421] [Cited by in Crossref: 81] [Cited by in F6Publishing: 66] [Article Influence: 16.2] [Reference Citation Analysis]
171 Kodama K, Kawaguchi T, Hyogo H, Nakajima T, Ono M, Seike M, Takahashi H, Nozaki Y, Kawanaka M, Tanaka S, Imajo K, Sumida Y, Kamada Y, Fujii H, Seko Y, Takehara T, Itoh Y, Nakajima A, Masaki N, Torimura T, Saibara T, Karino Y, Chayama K, Tokushige K. Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis. Journal of Gastroenterology and Hepatology 2019;34:1626-32. [DOI: 10.1111/jgh.14608] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
172 Singhal G, Kumar G, Chan S, Fisher FM, Ma Y, Vardeh HG, Nasser IA, Flier JS, Maratos-Flier E. Deficiency of fibroblast growth factor 21 (FGF21) promotes hepatocellular carcinoma (HCC) in mice on a long term obesogenic diet. Mol Metab. 2018;13:56-66. [PMID: 29753678 DOI: 10.1016/j.molmet.2018.03.002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 11.3] [Reference Citation Analysis]
173 Orci LA, Sanduzzi-Zamparelli M, Caballol B, Sapena V, Colucci N, Torres F, Bruix J, Reig M, Toso C. Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00505-X. [PMID: 33965578 DOI: 10.1016/j.cgh.2021.05.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
174 Peleg N, Sneh Arbib O, Issachar A, Cohen-Naftaly M, Braun M, Shlomai A. Noninvasive scoring systems predict hepatic and extra-hepatic cancers in patients with nonalcoholic fatty liver disease. PLoS One. 2018;13:e0202393. [PMID: 30106985 DOI: 10.1371/journal.pone.0202393] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
175 Singal AG, El-Serag HB. Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice. Clin Gastroenterol Hepatol. 2015;13:2140-2151. [PMID: 26284591 DOI: 10.1016/j.cgh.2015.08.014] [Cited by in Crossref: 269] [Cited by in F6Publishing: 257] [Article Influence: 44.8] [Reference Citation Analysis]
176 Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16:411-428. [PMID: 31028350 DOI: 10.1038/s41575-019-0145-7] [Cited by in Crossref: 268] [Cited by in F6Publishing: 241] [Article Influence: 134.0] [Reference Citation Analysis]
177 Toyoda H, Kumada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Tada T. Markedly lower follow-up rate after liver biopsy in patients with non-alcoholic fatty liver diseases than those with viral hepatitis in Japan. BMC Res Notes. 2011;4:341. [PMID: 21906297 DOI: 10.1186/1756-0500-4-341] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
178 Tanaka N, Kimura T, Fujimori N, Nagaya T, Komatsu M, Tanaka E. Current status, problems, and perspectives of non-alcoholic fatty liver disease research. World J Gastroenterol. 2019;25:163-177. [PMID: 30670907 DOI: 10.3748/wjg.v25.i2.163] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 32] [Article Influence: 23.5] [Reference Citation Analysis]
179 Dungubat E, Watabe S, Togashi-Kumagai A, Watanabe M, Kobayashi Y, Harada N, Yamaji R, Fukusato T, Lodon G, Sevjid B, Takahashi Y. Effects of Caffeine and Chlorogenic Acid on Nonalcoholic Steatohepatitis in Mice Induced by Choline-Deficient, L-Amino Acid-Defined, High-Fat Diet. Nutrients 2020;12:E3886. [PMID: 33353230 DOI: 10.3390/nu12123886] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
180 D'Avola D, Labgaa I, Villanueva A. Natural history of nonalcoholic steatohepatitis/nonalcoholic fatty liver disease-hepatocellular carcinoma: Magnitude of the problem from a hepatology clinic perspective. Clin Liver Dis (Hoboken) 2016;8:100-4. [PMID: 31041073 DOI: 10.1002/cld.579] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
181 Ballestri S, Nascimbeni F, Romagnoli D, Baldelli E, Targher G, Lonardo A. Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight. Int J Mol Sci. 2016;17:355. [PMID: 27005620 DOI: 10.3390/ijms17030355] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
182 Liew ZH, Goh GB, Hao Y, Chang PE, Tan CK. Comparison of Hepatocellular Carcinoma in Patients with Cryptogenic Versus Hepatitis B Etiology: A Study of 1079 Cases Over 3 Decades. Dig Dis Sci 2019;64:585-90. [PMID: 30327962 DOI: 10.1007/s10620-018-5331-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
183 Matsuura B, Nunoi H, Miyake T, Hiasa Y, Onji M. Obesity and gastrointestinal liver disorders in Japan. J Gastroenterol Hepatol. 2013;28 Suppl 4:48-53. [PMID: 24251704 DOI: 10.1111/jgh.12238] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
184 Qin J, Ru S, Wang W, Hao L, Ru Y, Wang J, Zhang X. Long-term bisphenol S exposure aggravates non-alcoholic fatty liver by regulating lipid metabolism and inducing endoplasmic reticulum stress response with activation of unfolded protein response in male zebrafish. Environmental Pollution 2020;263:114535. [DOI: 10.1016/j.envpol.2020.114535] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
185 Kawanaka M, Tomiyama Y, Hyogo H, Koda M, Shima T, Tobita H, Hiramatsu A, Nishino K, Okamoto T, Sato S, Hara Y, Nishina S, Kawamoto H, Chayama K, Okanoue T, Hino K. Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts the development of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. Hepatol Res 2018;48:521-8. [PMID: 29316028 DOI: 10.1111/hepr.13054] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
186 El Jabbour T, Lagana SM, Lee H. Update on hepatocellular carcinoma: Pathologists' review. World J Gastroenterol 2019;25:1653-65. [PMID: 31011252 DOI: 10.3748/wjg.v25.i14.1653] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 27] [Article Influence: 16.5] [Reference Citation Analysis]
187 Kopec KL, Burns D. Nonalcoholic fatty liver disease: a review of the spectrum of disease, diagnosis, and therapy. Nutr Clin Pract. 2011;26:565-576. [PMID: 21947639 DOI: 10.1177/0884533611419668] [Cited by in Crossref: 68] [Cited by in F6Publishing: 59] [Article Influence: 7.6] [Reference Citation Analysis]
188 Ryu JS, Lee M, Mun SJ, Hong SH, Lee HJ, Ahn HS, Chung KS, Kim GH, Son MJ. Targeting CYP4A attenuates hepatic steatosis in a novel multicellular organotypic liver model. J Biol Eng 2019;13:69. [PMID: 31406506 DOI: 10.1186/s13036-019-0198-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
189 Eguchi Y, Wong G, Lee EI, Akhtar O, Lopes R, Sumida Y. Epidemiology of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A focused literature review. JGH Open 2020;4:808-17. [PMID: 33102749 DOI: 10.1002/jgh3.12349] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
190 Perumpail RB, Liu A, Wong RJ, Ahmed A, Harrison SA. Pathogenesis of hepatocarcinogenesis in non-cirrhotic nonalcoholic fatty liver disease: Potential mechanistic pathways. World J Hepatol. 2015;7:2384-2388. [PMID: 26464753 DOI: 10.4254/wjh.v7.i22.2384] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
191 Eguchi Y, Wong G, Lee I, Akhtar O, Lopes R, Sumida Y. Hepatocellular carcinoma and other complications of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in Japan: A structured review of published works. Hepatol Res 2021;51:19-30. [DOI: 10.1111/hepr.13583] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
192 Kew MC. Obesity as a cause of hepatocellular carcinoma. Annals of Hepatology 2015;14:299-303. [DOI: 10.1016/s1665-2681(19)31267-0] [Cited by in Crossref: 10] [Article Influence: 1.7] [Reference Citation Analysis]
193 Zheng X, Liu W, Xiang J, Liu P, Ke M, Wang B, Wu R, Lv Y. Collagen I promotes hepatocellular carcinoma cell proliferation by regulating integrin β1/FAK signaling pathway in nonalcoholic fatty liver. Oncotarget 2017;8:95586-95. [PMID: 29221151 DOI: 10.18632/oncotarget.21525] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
194 Hashimoto E, Tokushige K. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Growing evidence of an epidemic? Hepatol Res. 2012;42:1-14. [PMID: 21917086 DOI: 10.1111/j.1872-034x.2011.00872.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 45] [Article Influence: 7.8] [Reference Citation Analysis]
195 Khneizer G, Rizvi S, Gawrieh S. Non-alcoholic Fatty Liver Disease and Diabetes Mellitus. Adv Exp Med Biol 2021;1307:417-40. [PMID: 32424494 DOI: 10.1007/5584_2020_532] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
196 Piscaglia F, Svegliati-Baroni G, Barchetti A, Pecorelli A, Marinelli S, Tiribelli C, Bellentani S; HCC-NAFLD Italian Study Group. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. Hepatology. 2016;63:827-838. [PMID: 26599351 DOI: 10.1002/hep.28368] [Cited by in Crossref: 270] [Cited by in F6Publishing: 233] [Article Influence: 54.0] [Reference Citation Analysis]
197 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1661] [Article Influence: 707.3] [Reference Citation Analysis]
198 Noureddin M, Rinella ME. Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. Clin Liver Dis 2015;19:361-79. [PMID: 25921668 DOI: 10.1016/j.cld.2015.01.012] [Cited by in Crossref: 94] [Cited by in F6Publishing: 76] [Article Influence: 15.7] [Reference Citation Analysis]
199 Mirrakhimov AE, Barbaryan A. Obstructive sleep apnea and cancer: is it time to study organ-specific cancers? Am J Respir Crit Care Med 2013;188:399. [PMID: 23905531 DOI: 10.1164/rccm.201301-0046LE] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
200 Teilhet C, Morvan D, Joubert-Zakeyh J, Biesse AS, Pereira B, Massoulier S, Dechelotte P, Pezet D, Buc E, Lamblin G, Peoc'h M, Porcheron J, Vasson MP, Abergel A, Demidem A. Specificities of Human Hepatocellular Carcinoma Developed on Non-Alcoholic Fatty Liver Disease in Absence of Cirrhosis Revealed by Tissue Extracts ¹H-NMR Spectroscopy. Metabolites 2017;7:E49. [PMID: 28937622 DOI: 10.3390/metabo7040049] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
201 Lonardo A, Nascimbeni F, Ballestri S, Fairweather D, Win S, Than TA, Abdelmalek MF, Suzuki A. Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. Hepatology. 2019;70:1457-1469. [PMID: 30924946 DOI: 10.1002/hep.30626] [Cited by in Crossref: 163] [Cited by in F6Publishing: 135] [Article Influence: 81.5] [Reference Citation Analysis]
202 Marjot T, Moolla A, Cobbold JF, Hodson L, Tomlinson JW. Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. Endocr Rev. 2020;41. [PMID: 31629366 DOI: 10.1210/endrev/bnz009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 30.0] [Reference Citation Analysis]
203 Huang Y, Wallace MC, Adams LA, MacQuillan G, Garas G, Ferguson J, Samuelson S, Tibballs J, Jeffrey GP. Rate of Nonsurveillance and Advanced Hepatocellular Carcinoma at Diagnosis in Chronic Liver Disease. J Clin Gastroenterol 2018;52:551-6. [PMID: 28858944 DOI: 10.1097/MCG.0000000000000916] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
204 Siow W, van der Poorten D, George J. Epidemiological Trends in NASH as a Cause for Liver Transplant. Curr Hepatology Rep 2016;15:67-74. [DOI: 10.1007/s11901-016-0294-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
205 Kumar R, Goh BG, Kam JW, Chang PE, Tan CK. Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma. Clin Mol Hepatol 2020;26:196-208. [PMID: 31914720 DOI: 10.3350/cmh.2019.0012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
206 Doyle MB, Vachharajani N, Maynard E, Shenoy S, Anderson C, Wellen JR, Lowell JA, Chapman WC. Liver transplantation for hepatocellular carcinoma: long-term results suggest excellent outcomes. J Am Coll Surg. 2012;215:19-28; discussion 28-30. [PMID: 22608403 DOI: 10.1016/j.jamcollsurg.2012.02.022] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
207 Leung C, Yeoh SW, Patrick D, Ket S, Marion K, Gow P, Angus PW. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease. World J Gastroenterol. 2015;21:1189-1196. [PMID: 25632192 DOI: 10.3748/wjg.v21.i4.1189] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 58] [Article Influence: 11.0] [Reference Citation Analysis]
208 Lin L, Yan L, Liu Y, Qu C, Ni J, Li H. The Burden and Trends of Primary Liver Cancer Caused by Specific Etiologies from 1990 to 2017 at the Global, Regional, National, Age, and Sex Level Results from the Global Burden of Disease Study 2017. Liver Cancer. 2020;9:563-582. [PMID: 33083281 DOI: 10.1159/000508568] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
209 Mittal S, El-Serag HB, Sada YH, Kanwal F, Duan Z, Temple S, May SB, Kramer JR, Richardson PA, Davila JA. Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2016;14:124-31.e1. [PMID: 26196445 DOI: 10.1016/j.cgh.2015.07.019] [Cited by in Crossref: 260] [Cited by in F6Publishing: 219] [Article Influence: 43.3] [Reference Citation Analysis]
210 Ashraf NU, Altaf M. Epigenetics: An emerging field in the pathogenesis of nonalcoholic fatty liver disease. Mutat Res Rev Mutat Res 2018;778:1-12. [PMID: 30454678 DOI: 10.1016/j.mrrev.2018.07.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
211 Jiang W, Huang S, Teng H, Wang P, Wu M, Zhou X, Ran H. Diagnostic accuracy of point shear wave elastography and transient elastography for staging hepatic fibrosis in patients with non-alcoholic fatty liver disease: a meta-analysis. BMJ Open 2018;8:e021787. [PMID: 30139901 DOI: 10.1136/bmjopen-2018-021787] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 12.7] [Reference Citation Analysis]
212 Chan TT, Chan WK, Wong GL, Chan AW, Nik Mustapha NR, Chan SL, Chong CC, Mahadeva S, Shu SS, Lai PB, Chan HL, Wong VW. Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Am J Gastroenterol. 2020;115:867-875. [PMID: 32149781 DOI: 10.14309/ajg.0000000000000588] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
213 Italian Association for the Study of the Liver (AISF). AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. Dig Liver Dis. 2017;49:471-483. [PMID: 28215516 DOI: 10.1016/j.dld.2017.01.147] [Cited by in Crossref: 161] [Cited by in F6Publishing: 144] [Article Influence: 40.3] [Reference Citation Analysis]
214 Adhoute X, Penaranda G, Castellani P, Perrier H, Bourliere M. Recommendations for the use of chemoembolization in patients with hepatocellular carcinoma: Usefulness of scoring system? World J Hepatol. 2015;7:521-531. [PMID: 25848475 DOI: 10.4254/wjh.v7.i3.521] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
215 Kettner NM, Voicu H, Finegold MJ, Coarfa C, Sreekumar A, Putluri N, Katchy CA, Lee C, Moore DD, Fu L. Circadian Homeostasis of Liver Metabolism Suppresses Hepatocarcinogenesis. Cancer Cell 2016;30:909-24. [PMID: 27889186 DOI: 10.1016/j.ccell.2016.10.007] [Cited by in Crossref: 190] [Cited by in F6Publishing: 155] [Article Influence: 38.0] [Reference Citation Analysis]
216 Van Herck MA, Vonghia L, Francque SM. Animal Models of Nonalcoholic Fatty Liver Disease-A Starter's Guide. Nutrients. 2017;9:1072. [PMID: 28953222 DOI: 10.3390/nu9101072] [Cited by in Crossref: 113] [Cited by in F6Publishing: 90] [Article Influence: 28.3] [Reference Citation Analysis]
217 Medici V. The Evolving Scenario of Copper and Fatty Liver. Metabolic Syndrome and Related Disorders 2013;11:4-6. [DOI: 10.1089/met.2013.1501] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
218 Li T, Zhang G, Wang L, Li S, Xu X, Gao Y. Defects in mTORC1 Network and mTORC1-STAT3 Pathway Crosstalk Contributes to Non-inflammatory Hepatocellular Carcinoma. Front Cell Dev Biol. 2020;8:225. [PMID: 32363190 DOI: 10.3389/fcell.2020.00225] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
219 Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317-370. [PMID: 28620797 DOI: 10.1007/s12072-017-9799-9] [Cited by in Crossref: 661] [Cited by in F6Publishing: 576] [Article Influence: 165.3] [Reference Citation Analysis]
220 Raza S, Rajak S, Anjum B, Sinha RA. Molecular links between non-alcoholic fatty liver disease and hepatocellular carcinoma. Hepatoma Res 2019;5:42. [PMID: 31867441 DOI: 10.20517/2394-5079.2019.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
221 Mindikoglu AL, Opekun AR, Gagan SK, Devaraj S. Impact of Time-Restricted Feeding and Dawn-to-Sunset Fasting on Circadian Rhythm, Obesity, Metabolic Syndrome, and Nonalcoholic Fatty Liver Disease. Gastroenterol Res Pract 2017;2017:3932491. [PMID: 29348746 DOI: 10.1155/2017/3932491] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
222 Benhammou JN, Lin J, Hussain SK, El-Kabany M. Emerging risk factors for nonalcoholic fatty liver disease associated hepatocellular carcinoma. Hepatoma Res 2020;6:35. [PMID: 32685690 DOI: 10.20517/2394-5079.2020.16] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
223 Liu K, Mccaughan GW. Epidemiology and Etiologic Associations of Non-alcoholic Fatty Liver Disease and Associated HCC. In: Yu J, editor. Obesity, Fatty Liver and Liver Cancer. Singapore: Springer; 2018. pp. 3-18. [DOI: 10.1007/978-981-10-8684-7_2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
224 Welzel TM, Graubard BI, Quraishi S, Zeuzem S, Davila JA, El-Serag HB, McGlynn KA. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol. 2013;108:1314-1321. [PMID: 23752878 DOI: 10.1038/ajg.2013.160] [Cited by in Crossref: 201] [Cited by in F6Publishing: 172] [Article Influence: 25.1] [Reference Citation Analysis]
225 Rahimi RS, Landaverde C. Nonalcoholic fatty liver disease and the metabolic syndrome: clinical implications and treatment. Nutr Clin Pract. 2013;28:40-51. [PMID: 23286927 DOI: 10.1177/0884533612470464] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
226 Younes R, Bugianesi E. Should we undertake surveillance for HCC in patients with NAFLD? Journal of Hepatology 2018;68:326-34. [DOI: 10.1016/j.jhep.2017.10.006] [Cited by in Crossref: 76] [Cited by in F6Publishing: 60] [Article Influence: 25.3] [Reference Citation Analysis]